Ironwood Pharma (IRWD) Reports Q2 Loss Per Share of 34c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
August 5, 2015 4:01 PM EDTLINZESS® (linaclotide) U.S. net sales of $112.1 million in second quarter 2015
Total LINZESS prescriptions increased approximately 56% in second quarter 2015 compared to second quarter 2014
Advanced innovative pipeline, including positive top-line Phase I data with sGC stimulator IW-1973
Entered agreement with Allergan to co-promote VIBERZI (eluxadoline) for IBS-D
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals,... More
